Latest Period
Q1 2026
Security Snapshot
Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) Institutional Ownership
CUSIP: 45254E107
13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026
Institutions Reporting
94
Shares (Excl. Options)
29,159,156
Price
$5.27
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A common stock, par value $0.001 per share
- Symbol
- IMRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 29,159,156
- Total 13F value
- $153,669,193
- Portfolio coverage rank
- 0%
- Share change
- -2,348,454
- Value change
- -$17,708,157
- Number of holders
- 94
- Shares outstanding
- 66,027,379
- SEC-reported price per share
- $5.20
- Insider filing price
- $5.20
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMRX - Immuneering Corp - Class A common stock, par value $0.001 per share is tracked under CUSIP 45254E107.
- 94 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 87 to 94 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $208,911,171 to $153,669,193.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 94 institutions filings for Q1 2026.
Security key
45254E107
Latest holder period
Q1 2026
13F holders
94
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
IMRX full holder history
Immuneering Corp SEC filings
Immuneering Corp company facts
Immuneering Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45254E107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
IMRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | $71,526,603 | 8,787,052 | FMR LLC | 30 Sep 2025 | |||
| Zeskind Benjamin J. | 6.6% | -48% | $28,674,370 | +$2,498,025 | 4,357,807 | +9.5% | BENJAMIN J. ZESKIND | 31 Dec 2025 |
| HBM Healthcare Investments (Cayman) Ltd. | 5.7% | $29,680,915 | 3,646,304 | HBM Healthcare Investments (Cayman) Ltd. | 26 Sep 2025 | |||
| Empery Asset Management, LP | 5% | -43% | $20,154,805 | -$12,015,476 | 3,250,775 | -37% | Empery Asset Management, LP | 31 Dec 2025 |
As of 31 Mar 2026, 94 institutional investors reported holding 29,159,156 shares of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX). This represents 44% of the company’s total 66,027,379 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
40%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 9,697,938 | +0.13% | 0% | $51,108,133 |
| Sanofi | 4.1% | 2,708,559 | 0% | 4.2% | $14,274,106 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,288,341 | 0% | 0% | $12,059,557 |
| MARSHALL WACE, LLP | 3% | 1,996,585 | +180% | 0.01% | $10,522,002 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.8% | 1,829,188 | -8.3% | 0% | $9,640,000 |
| BlackRock, Inc. | 2.3% | 1,507,258 | +3.8% | 0% | $7,943,249 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 1,102,712 | +2065% | 0% | $5,811,292 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.97% | 637,944 | +3.2% | 0% | $3,363,708 |
| Occam Crest Management LP | 0.83% | 545,098 | +9.3% | 1.8% | $2,872,666 |
| CITADEL ADVISORS LLC | 0.68% | 447,278 | +394% | 0% | $2,357,155 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.61% | 400,363 | +202% | 0% | $2,109,913 |
| Summit Financial, LLC | 0.57% | 376,749 | 0.03% | $1,985,467 | |
| UBS Group AG | 0.57% | 376,284 | +98% | 0% | $1,983,017 |
| GOLDMAN SACHS GROUP INC | 0.5% | 327,655 | +2.8% | 0% | $1,726,742 |
| VANGUARD FIDUCIARY TRUST CO | 0.49% | 322,038 | 0% | 0% | $1,697,140 |
| Burkehill Global Management, LP | 0.45% | 300,000 | 0% | 0.08% | $1,581,000 |
| MORGAN STANLEY | 0.45% | 296,067 | -40% | 0% | $1,560,273 |
| STATE STREET CORP | 0.41% | 268,520 | -89% | 0% | $1,415,100 |
| TWO SIGMA INVESTMENTS, LP | 0.37% | 244,771 | +18% | 0% | $1,289,943 |
| Squarepoint Ops LLC | 0.34% | 226,046 | +145% | 0% | $1,191,262 |
| Diametric Capital, LP | 0.26% | 174,897 | -29% | 0.24% | $921,707 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.24% | 156,424 | 0% | $824,355 | |
| BANK OF AMERICA CORP /DE/ | 0.23% | 150,847 | -30% | 0% | $794,963 |
| 683 Capital Management, LLC | 0.23% | 150,697 | 0% | 0.07% | $794,173 |
| DCF Advisers, LLC | 0.21% | 141,462 | -34% | 0.28% | $745,505 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q1 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 29,159,156 | $153,669,193 | -$17,708,157 | $5.27 | 94 |
| 2025 Q4 | 31,752,244 | $208,911,171 | +$18,277,430 | $6.58 | 87 |
| 2025 Q3 | 26,061,962 | $182,434,908 | +$152,080,293 | $7.00 | 69 |
| 2025 Q2 | 3,829,641 | $12,906,115 | -$684,732 | $3.37 | 39 |
| 2025 Q1 | 4,498,583 | $6,835,562 | +$160,625 | $1.52 | 34 |
| 2024 Q4 | 4,238,711 | $9,324,244 | -$178,796 | $2.20 | 41 |
| 2024 Q3 | 4,355,017 | $10,869,922 | -$7,529,696 | $2.49 | 38 |
| 2024 Q2 | 9,594,278 | $12,279,759 | -$9,114,134 | $1.28 | 57 |
| 2024 Q1 | 11,871,050 | $34,309,079 | -$12,746,356 | $2.89 | 50 |
| 2023 Q4 | 16,130,676 | $118,561,919 | -$6,044,147 | $7.35 | 52 |
| 2023 Q3 | 16,940,765 | $130,107,793 | -$5,076,687 | $7.68 | 52 |
| 2023 Q2 | 17,269,962 | $175,881,466 | +$55,986,602 | $10.14 | 49 |
| 2023 Q1 | 11,823,558 | $114,882,649 | +$3,734,772 | $9.71 | 34 |
| 2022 Q4 | 11,722,865 | $56,864,840 | -$4,241,513 | $4.85 | 32 |
| 2022 Q3 | 12,063,607 | $172,475,348 | -$5,229,083 | $14.32 | 30 |
| 2022 Q2 | 12,148,741 | $65,706,270 | -$8,960,781 | $5.41 | 33 |
| 2022 Q1 | 13,611,716 | $88,116,760 | -$3,464,272 | $6.47 | 49 |
| 2021 Q4 | 12,489,185 | $199,826,000 | +$5,452,786 | $16.17 | 36 |
| 2021 Q3 | 12,105,226 | $316,421,451 | +$316,421,451 | $26.55 | 38 |